Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.59 |
| ▸ | IGF1R | P08069 | 8/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162039 | 0.90 | NTRK1 (0.62) | NTRK1IGF1RJAK2 | |
| SCHEMBL15208531 | 0.85 | PAK1 (0.50) | NTRK1IGF1RJAK2 | |
| SCHEMBL15208437 | 0.84 | PAK1 (0.58) | NTRK1IGF1R | |
| SCHEMBL4077928 | 0.84 | NTRK1 (0.49) | NTRK1IGF1R | |
| SCHEMBL220866 | 0.83 | JAK2 (0.61) | NTRK1JAK2 | |
| SCHEMBL589564 | 0.82 | NTRK1 (0.63) | NTRK1IGF1RJAK2 | |
| SCHEMBL4073775 | 0.82 | NTRK1 (0.47) | NTRK1IGF1RCCNA2CDK2CCNA1 | |
| SCHEMBL589514 | 0.82 | NTRK1 (0.51) | NTRK1IGF1RJAK2 | |
| SCHEMBL4151428 | 0.82 | NTRK1 (0.49) | NTRK1IGF1RCCNA2CDK2CCNA1 | |
| SCHEMBL4070836 | 0.81 | JAK2 (0.40) | NTRK1IGF1RJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885IGF1R 4775/4885JAK2 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.